Dong-A ST said Wednesday it signed a business agreement with Korean medical AI company Mediwhale to distribute its AI-powered retinal screening tools nationwide.
Under the deal, finalized Tuesday at Dong-A ST’s Seoul headquarters, the pharma company will take on domestic sales, marketing, and distribution of Mediwhale’s AI software, including Dr. Noon CVD and Dr. Noon Fundus.
The tools analyze retinal images to assess cardiovascular risk and identify eye diseases, aiming to shift healthcare from treatment to prevention.
Dr. Noon CVD estimates future cardiovascular disease risk using retinal scans, with accuracy comparable to cardiac CT, according to Mediwhale. The software is currently deployed at more than 90 hospitals in Korea and over 100 globally, including Severance Hospital in Seoul, GluCare in Dubai, and Italy’s NephroCenter network.
출처 : KBR(https://www.koreabiomed.com)